| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerate the elimination of rubella through supplementary immunisation activities in China
|
Chong, Ka Chun
|
|
|
21 |
7 |
p. 899-900
|
artikel
|
| 2 |
Acute superior mesenteric vein thrombosis in the setting of cytomegalovirus mononucleosis: a case report and review of the literature
|
Walter, Graham
|
|
|
21 |
7 |
p. e202-e207
|
artikel
|
| 3 |
A decentralised point-of-care testing model to address inequities in the COVID-19 response
|
Hengel, Belinda
|
|
|
21 |
7 |
p. e183-e190
|
artikel
|
| 4 |
Adjuvantation helps to optimise COVID-19 vaccine candidate
|
Li, Jing-Xin
|
|
|
21 |
7 |
p. 891-893
|
artikel
|
| 5 |
Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19
|
Hamilton, William L
|
|
|
21 |
7 |
p. 916-917
|
artikel
|
| 6 |
A prescription for fair housing during the COVID-19 pandemic
|
Hussaini, Syed M Qasim
|
|
|
21 |
7 |
p. 903-905
|
artikel
|
| 7 |
Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study
|
Su, Qiru
|
|
|
21 |
7 |
p. 1004-1013
|
artikel
|
| 8 |
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial
|
Prentice, Sarah
|
|
|
21 |
7 |
p. 993-1003
|
artikel
|
| 9 |
BCG: new life for a centenarian vaccine
|
Aaby, Peter
|
|
|
21 |
7 |
p. 897-898
|
artikel
|
| 10 |
Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring
|
Hewison, Catherine
|
|
|
21 |
7 |
p. 894-895
|
artikel
|
| 11 |
Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy
|
Mehta, Puja
|
|
|
21 |
7 |
p. 912
|
artikel
|
| 12 |
Chlorhexidine for skin antisepsis: making the case to keep peripheral venous catheters CLEAN
|
Advani, Sonali D
|
|
|
21 |
7 |
p. 902-903
|
artikel
|
| 13 |
Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial
|
Guenezan, Jérémy
|
|
|
21 |
7 |
p. 1038-1048
|
artikel
|
| 14 |
Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India
|
Balsari, Satchit
|
|
|
21 |
7 |
p. 905-907
|
artikel
|
| 15 |
Correction to Lancet Infect Dis 2021; 21: 677–87
|
|
|
|
21 |
7 |
p. e182
|
artikel
|
| 16 |
Correction to Lancet Infect Dis 2020; published online Dec 23. https://doi.org/10.1016/S1473-3099(20)30859-8
|
|
|
|
21 |
7 |
p. e182
|
artikel
|
| 17 |
Correction to Lancet Infect Dis 2021; published online March 25. https://doi.org/10.1016/S1473-3099(21)00132-8
|
|
|
|
21 |
7 |
p. e182
|
artikel
|
| 18 |
Correction to Lancet Infect Dis 2021; published online May 20. https://doi.org/10.1016/S1473-3099(20)30765-9
|
|
|
|
21 |
7 |
p. e182
|
artikel
|
| 19 |
Cross-protective potential of a MF59-adjuvanted quadrivalent influenza vaccine in older adults
|
Isakova-Sivak, Irina
|
|
|
21 |
7 |
p. 900-901
|
artikel
|
| 20 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy
|
Jeng, Wen-Juei
|
|
|
21 |
7 |
p. 910-911
|
artikel
|
| 21 |
Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy – Authors' reply
|
Hsu, Yao-Chun
|
|
|
21 |
7 |
p. 911
|
artikel
|
| 22 |
Global COVID-19 vaccine inequity
|
Burki, Talha
|
|
|
21 |
7 |
p. 922-923
|
artikel
|
| 23 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
21 |
7 |
p. 923
|
artikel
|
| 24 |
Lemierre's syndrome following infectious mononucleosis: an unusual reason for neck pain
|
Maier-Stocker, Constantin
|
|
|
21 |
7 |
p. 1050
|
artikel
|
| 25 |
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases
|
Trunfio, Mattia
|
|
|
21 |
7 |
p. 914-915
|
artikel
|
| 26 |
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases – Authors' reply
|
Spinelli, Matthew A
|
|
|
21 |
7 |
p. 915-916
|
artikel
|
| 27 |
Mask confusion in NYC with abrupt CDC guidance changes
|
Larkin, Marilynn
|
|
|
21 |
7 |
p. 921
|
artikel
|
| 28 |
Measles immunisation gaps in Africa
|
Bagcchi, Sanjeet
|
|
|
21 |
7 |
p. 918
|
artikel
|
| 29 |
Navigating post-vaccine COVID-19 futures in the health and economic context
|
MacIntyre, C Raina
|
|
|
21 |
7 |
p. 893-894
|
artikel
|
| 30 |
Nina Chanishvili—keeping bacteriophages in the limelight
|
Kirby, Tony
|
|
|
21 |
7 |
p. 926
|
artikel
|
| 31 |
Oropharyngeal lymphogranuloma venereum
|
Kapoor, Andrew
|
|
|
21 |
7 |
p. 1049
|
artikel
|
| 32 |
Placing in-vitro heteroresistance in the context of clinical results
|
Bassetti, Matteo
|
|
|
21 |
7 |
p. 908-909
|
artikel
|
| 33 |
Post-disruption catch-up of child immunisation and health-care services in Bangladesh
|
Rana, Shohel
|
|
|
21 |
7 |
p. 913
|
artikel
|
| 34 |
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study
|
Beran, Jiří
|
|
|
21 |
7 |
p. 1027-1037
|
artikel
|
| 35 |
Proposing an antibacterial mouthwash to prevent gonorrhoea is not sexy
|
Rotsaert, Anke
|
|
|
21 |
7 |
p. 909
|
artikel
|
| 36 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
|
Dooley, Kelly E
|
|
|
21 |
7 |
p. 975-983
|
artikel
|
| 37 |
Quantifying the global number of tuberculosis survivors: a modelling study
|
Dodd, Peter J
|
|
|
21 |
7 |
p. 984-992
|
artikel
|
| 38 |
Rajendra Kapila
|
Bagcchi, Sanjeet
|
|
|
21 |
7 |
p. 925
|
artikel
|
| 39 |
Research in brief
|
Devi, Sharmila
|
|
|
21 |
7 |
p. 924
|
artikel
|
| 40 |
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis
|
Sangkaew, Sorawat
|
|
|
21 |
7 |
p. 1014-1026
|
artikel
|
| 41 |
Role of the G20 in safe reopening of international travel
|
Pandey, Abhishek
|
|
|
21 |
7 |
p. 919
|
artikel
|
| 42 |
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study
|
Kiang, Mathew V
|
|
|
21 |
7 |
p. 929-938
|
artikel
|
| 43 |
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
|
Ella, Raches
|
|
|
21 |
7 |
p. 950-961
|
artikel
|
| 44 |
SARS-CoV-2 incidence and vaccine escape
|
Thompson, Robin N
|
|
|
21 |
7 |
p. 913-914
|
artikel
|
| 45 |
Should we vaccinate children against SARS-CoV-2?
|
The Lancet Infectious Diseases,
|
|
|
21 |
7 |
p. 889
|
artikel
|
| 46 |
Symptom study app provides real-world data on COVID-19 vaccines
|
Drury, Ruth E
|
|
|
21 |
7 |
p. 890-891
|
artikel
|
| 47 |
The eternal cycle of pandemics
|
Pascal, Genevieve
|
|
|
21 |
7 |
p. 928
|
artikel
|
| 48 |
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation
|
Sandmann, Frank G
|
|
|
21 |
7 |
p. 962-974
|
artikel
|
| 49 |
To give or not to give antibiotics is not the only question
|
Magalhães, Catarina
|
|
|
21 |
7 |
p. e191-e201
|
artikel
|
| 50 |
Tuberculosis care does not end at treatment completion— a perspective from tuberculosis survivors
|
Schoeman, Ingrid
|
|
|
21 |
7 |
p. 896-897
|
artikel
|
| 51 |
Uganda's Sexual Offences Bill—a step backwards
|
Nakkazi, Esther
|
|
|
21 |
7 |
p. 920
|
artikel
|
| 52 |
Vaccine development for dummies
|
Balakrishnan, Vijay Shankar
|
|
|
21 |
7 |
p. 927
|
artikel
|
| 53 |
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
|
Menni, Cristina
|
|
|
21 |
7 |
p. 939-949
|
artikel
|
Tijdschrift beschrijving